Skip to main content

Guideline Adherence Suboptimal for Chlamydia, Gonorrhea Treatment

Medically reviewed by Drugs.com. Last updated on March 31, 2025.

By Elana Gotkine HealthDay Reporter

MONDAY, March 31, 2025 -- Across primary care practices, guideline adherence remains suboptimal for chlamydia and gonorrhea, according to a study published in the March/April issue of the Annals of Family Medicine.

Shiying Hao, Ph.D., from Stanford University in California, and colleagues used electronic health records to identify patients with diagnosis codes or positive test results for chlamydia and/or gonorrhea from 2018 to 2022 to examine how well treatment in primary care settings adhered to guidelines.

The researchers found that 75.3 percent of the 6,678 cases of chlamydia and 69.6 percent of the 2,206 cases of gonorrhea were treated. Higher treatment rates were seen for females, individuals aged 10 to 29 years, suburban dwellers, and patients with chlamydia-gonorrhea coinfection. Treatment with the recommended antibiotic occurred infrequently (14.0 percent of chlamydia cases were treated with doxycycline; 38.7 percent of gonorrhea cases were treated with ceftriaxone). Patients aged 50 to 59 years and non-Hispanic Blacks had longer time to treatment for chlamydia (time ratios, 1.61 relative to those aged 20 to 29 years and 1.17 relative to Whites).

"Given the importance of timely treatment for these sexually transmitted infections to curb the spread of infection, there remains substantial opportunity to improve treatment rates across all patient groups, with particular attention directed to those in vulnerable populations," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted March 2025

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.